Literature DB >> 25132262

N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochore-microtubule dynamics.

M Orticello1, M Fiore1, P Totta1, M Desideri2, M Barisic3, D Passeri4, J Lenzi5, A Rosa5, A Orlandi4, H Maiato6, D Del Bufalo2, F Degrassi1.   

Abstract

Mitotic proteins are attractive targets to develop molecular cancer therapeutics due to the intimate interdependence between cell proliferation and mitosis. In this work, we have explored the therapeutic potential of the kinetochore (KT) protein Hec1 (Highly Expressed in Cancer protein 1) as a molecular target to produce massive chromosome missegregation and cell death in cancer cells. Hec1 is a constituent of the Ndc80 complex, which mediates KT-microtubule (MT) attachments at mitosis and is upregulated in various cancer types. We expressed Hec1 fused with enhanced green fluorescent protein (EGFP) at its N-terminus MT-interaction domain in HeLa cells and showed that expression of this modified Hec1, which localized at KTs, blocked cell proliferation and promoted apoptosis in tumour cells. EGFP-Hec1 was extremely potent in tumour cell killing and more efficient than siRNA-induced Hec1 depletion. In striking contrast, normal cells showed no apparent cell proliferation defects or cell death following EGFP-Hec1 expression. Live-cell imaging demonstrated that cancer cell death was associated with massive chromosome missegregation within multipolar spindles after a prolonged mitotic arrest. Moreover, EGFP-Hec1 expression was found to increase KT-MT attachment stability, providing a molecular explanation for the abnormal spindle architecture and the cytotoxic activity of this modified protein. Consistent with cell culture data, EGFP-Hec1 expression was found to strongly inhibit tumour growth in a mouse xenograft model by disrupting mitosis and inducing multipolar spindles. Taken together, these findings demonstrate that stimulation of massive chromosome segregation defects can be used as an anti-cancer strategy through the activation of mitotic catastrophe after a multipolar mitosis. Importantly, this study represents a clear proof of concept that targeting KT proteins required for proper KT-MT attachment dynamics constitutes a powerful approach in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25132262     DOI: 10.1038/onc.2014.265

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

1.  Implications for kinetochore-microtubule attachment from the structure of an engineered Ndc80 complex.

Authors:  Claudio Ciferri; Sebastiano Pasqualato; Emanuela Screpanti; Gianluca Varetti; Stefano Santaguida; Gabriel Dos Reis; Alessio Maiolica; Jessica Polka; Jennifer G De Luca; Peter De Wulf; Mogjiborahman Salek; Juri Rappsilber; Carolyn A Moores; Edward D Salmon; Andrea Musacchio
Journal:  Cell       Date:  2008-05-02       Impact factor: 41.582

2.  HEC, a novel nuclear protein rich in leucine heptad repeats specifically involved in mitosis.

Authors:  Y Chen; D J Riley; P L Chen; W H Lee
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

Authors:  Gennadi V Glinsky; Olga Berezovska; Anna B Glinskii
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

4.  RNA interference against Hec1 inhibits tumor growth in vivo.

Authors:  E N Gurzov; M Izquierdo
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

5.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

6.  Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.

Authors:  Hsiao-Chun Huang; Jue Shi; James D Orth; Timothy J Mitchison
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

7.  Uncoordinated loss of chromatid cohesion is a common outcome of extended metaphase arrest.

Authors:  Deanna Stevens; Reto Gassmann; Karen Oegema; Arshad Desai
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

8.  Biscarbamate cross-linked polyethylenimine derivative with low molecular weight, low cytotoxicity, and high efficiency for gene delivery.

Authors:  Yu-Qiang Wang; Jing Su; Fei Wu; Ping Lu; Li-Fen Yuan; Wei-En Yuan; Jing Sheng; Tuo Jin
Journal:  Int J Nanomedicine       Date:  2012-02-09

9.  Kinetochore microtubule dynamics and the metaphase-anaphase transition.

Authors:  Y Zhai; P J Kronebusch; G G Borisy
Journal:  J Cell Biol       Date:  1995-11       Impact factor: 10.539

10.  Genome stability is ensured by temporal control of kinetochore-microtubule dynamics.

Authors:  Samuel F Bakhoum; Sarah L Thompson; Amity L Manning; Duane A Compton
Journal:  Nat Cell Biol       Date:  2008-12-07       Impact factor: 28.824

View more
  6 in total

Review 1.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

2.  Kinetochore-microtube attachments in cancer therapy.

Authors:  Donatella Del Bufalo; Francesca Degrassi
Journal:  Oncoscience       Date:  2015-11-16

3.  Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells.

Authors:  Moshe Giladi; Rosa S Schneiderman; Tali Voloshin; Yaara Porat; Mijal Munster; Roni Blat; Shay Sherbo; Zeev Bomzon; Noa Urman; Aviran Itzhaki; Shay Cahal; Anna Shteingauz; Aafia Chaudhry; Eilon D Kirson; Uri Weinberg; Yoram Palti
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

4.  Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization.

Authors:  M Ferrara; G Sessa; M Fiore; F Bernard; I A Asteriti; E Cundari; G Colotti; S Ferla; M Desideri; S Buglioni; D Trisciuoglio; D Del Bufalo; A Brancale; F Degrassi
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

Review 5.  New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy Response.

Authors:  Nelson Rangel; Maribel Forero-Castro; Milena Rondón-Lagos
Journal:  Genes (Basel)       Date:  2017-06-03       Impact factor: 4.096

6.  Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer.

Authors:  Xuebing Yan; Linsheng Huang; Liguo Liu; Huanlong Qin; Zhenshun Song
Journal:  Cancer Med       Date:  2018-01-17       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.